@article{7bd33d63c0d24779a8767b380425c0a4,
title = "Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial",
abstract = "This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.",
keywords = "Anti-TNF, DMARDs (biologic), Disease Activity, Rheumatoid Arthritis, Anti-TNF, DMARDs (biologic), Disease Activity, Rheumatoid Arthritis",
author = "Gianfranco Ferraccioli and Smolen, {J. S.} and P. Emery and W. Samborski and F. Berenbaum and Davies, {O. R.} and W. Koetse and O. Purcaru and B. Bennett and H. Burkhardt",
year = "2014",
doi = "10.1136/annrheumdis-2013-204632",
language = "English",
pages = "N/A--N/A",
journal = "ANNALS OF THE RHEUMATIC DISEASES",
issn = "0003-4967",
publisher = "London, United Kingdom: BMJ / British Medical Journal Publishing Group",
}